Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta‐analyses
Top Cited Papers
- 14 December 2009
- journal article
- review article
- Published by Wiley in Clinical Endocrinology
- Vol. 72 (1), 1-10
- https://doi.org/10.1111/j.1365-2265.2009.03632.x
Abstract
P>Objective To summarize the available evidence on the cardiovascular effects of cross-sex steroid use in transsexuals. Methods We searched relevant electronic databases and sought additional references from experts. Eligible studies reported on cardiovascular events, venous thromboembolism, blood pressure and fasting serum lipids. Data were extracted in duplicate. We used the random-effects model to estimate the pooled weighted mean difference (WMD) and 95% confidence intervals (CIs). Results We found 16 eligible studies, mostly uncontrolled cohorts of varied follow-up durations (1471 male-to-female (MF) and 651 female-to-male (FM) individuals). In the MF individuals, cross-sex hormone use was associated with a statistically significant increase in fasting serum triglycerides without changes in the other parameters (WMD = 23 center dot 39 mg/dl; 95% CI = 4 center dot 82-41 center dot 95). In the FM individuals, there was a similar increase of triglycerides (WMD = 31 center dot 35 mg/dl; 95% CI = 7 center dot 53-55 center dot 17) and a reduction of high density lipoprotein (HDL)-cholesterol (WMD = -6 center dot 09 mg/dl; 95% CI = -11 center dot 44 to -0 center dot 73). There was a statistically significant but clinically trivial increase in systolic blood pressure (WMD = 1 center dot 74 mmHg; 95% CI = 0 center dot 21-3 center dot 27). Analyses were associated with significant heterogeneity across studies. There were very few reported cardiovascular events (deaths, strokes, myocardial infarctions or venous thromboembolism), more commonly among MF individuals. Conclusions Very low quality evidence, downgraded due to methodological limitations of included studies, imprecision and heterogeneity, suggests that cross-sex hormone therapies increase serum triglycerides in MF and FM and have a trivial effect on HDL-cholesterol and systolic blood pressure in FM. Data about patient important outcomes are sparse and inconclusive.Keywords
This publication has 35 references indexed in Scilit:
- A Case for Clarity, Consistency, and Helpfulness: State-of-the-Art Clinical Practice Guidelines in Endocrinology Using the Grading of Recommendations, Assessment, Development, and Evaluation SystemJournal of Clinical Endocrinology & Metabolism, 2008
- Long-Acting Intramuscular Testosterone Undecanoate for Treatment of Female-to-Male Transgender IndividualsThe Journal of Sexual Medicine, 2007
- Effects on the Male Endocrine System of Long-term Treatment with Gonadotropin-releasing Hormone Agonists and Estrogens in Male-to-Female TranssexualsHormone and Metabolic Research, 2006
- Sexual and Physical Health After Sex Reassignment SurgeryArchives of Sexual Behavior, 2005
- Endocrine Treatment of Male-to-Female Transsexuals Using Gonadotropin-Releasing Hormone AgonistExperimental and Clinical Endocrinology & Diabetes, 2005
- Measuring inconsistency in meta-analysesBMJ, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Visceral Fat Accumulation Is an Important Determinant of PAI-1 Levels in Young, Nonobese Men and WomenArteriosclerosis, Thrombosis, and Vascular Biology, 1998
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986